Thermo Fisher Scientific (NYSE:TMO) Issues FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 24.640-25.120 for the period, compared to the consensus EPS estimate of 24.770. The company issued revenue guidance of $47.3 billion-$48.1 billion, compared to the consensus revenue estimate of $47.5 billion.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Robert W. Baird set a $653.00 price target on Thermo Fisher Scientific in a research report on Friday, January 30th. Stifel Nicolaus lifted their price target on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a research report on Friday, January 9th. TD Cowen lowered their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Evercore reaffirmed an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $631.25.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $53.47 during trading on Thursday, reaching $460.51. The company had a trading volume of 2,661,263 shares, compared to its average volume of 2,274,602. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The firm has a market capitalization of $171.14 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 2.72 and a beta of 0.97. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $643.99. The firm’s 50-day simple moving average is $500.69 and its 200 day simple moving average is $550.56.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific will post 24.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.60%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by insiders.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 beat — Thermo Fisher posted adjusted EPS of $5.44 and revenue of $11.01B, topping consensus and showing 6.2% year-over-year sales growth; bottom-line and top-line beats are supportive for near-term earnings credibility. Q1 Earnings & Revenues Top Estimates
• Positive Sentiment: Analyst support — Some sell-side analysts remain constructive (Buy reiterations highlight confidence in core growth, reshoring and AI-related opportunities), which can limit downside versus peers. Buy Rating Reiterated
• Neutral Sentiment: Guidance published — Management updated FY2026 guidance to an EPS range of 24.640–25.120 and revenue $47.3B–$48.1B; the range broadly brackets consensus but the midpoint is marginally below some expectations, leaving room for interpretation by investors. Company Press Release
• Negative Sentiment: Muted underlying growth & cautious tone — Commentators flagged that underlying organic growth was muted and management’s commentary remained cautious even after a revenue upgrade, which undercut enthusiasm despite the beat. This narrative drove selling pressure. Thermo Fisher falls after earnings top estimates, but growth concerns persist
• Negative Sentiment: Mixed segment performance — Strength in lab products and biopharma services was offset by softness in analytical instruments and specialty diagnostics, raising execution/questions about sustainability of growth across the business. Market reaction showed a pre-/post-market decline despite the beat. Reuters: Quarterly Results Beat

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its holdings in Thermo Fisher Scientific by 0.7% in the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 20 shares during the last quarter. Challenger Wealth Management increased its holdings in shares of Thermo Fisher Scientific by 3.1% during the 2nd quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock worth $298,000 after buying an additional 22 shares during the last quarter. Johnson Financial Group Inc. raised its position in shares of Thermo Fisher Scientific by 1.3% during the 4th quarter. Johnson Financial Group Inc. now owns 1,746 shares of the medical research company’s stock valued at $1,012,000 after buying an additional 22 shares during the period. Finally, Security National Bank of Sioux City Iowa IA grew its position in Thermo Fisher Scientific by 0.3% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock worth $2,655,000 after acquiring an additional 22 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.